NCT05733689 2026-03-10
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Phase 1 Recruiting
Clinical Trials
43 trialsNCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
NCT00208260 2026-02-05
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2/3 Completed
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT07359456 2026-01-22
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT05008809 2025-12-12
AIO-KRK-0418
Charite University, Berlin, Germany
Phase 3 Recruiting
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06867822 2025-08-24
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
University of Alabama at Birmingham
Phase 1 Recruiting
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT07021950 2025-06-15
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06640166 2025-02-12
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT03081143 2024-12-12
RAMIRIS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2/3 Active not recruiting
NCT03959293 2024-07-08
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT04259944 2023-09-28
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Unknown
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT05634590 2022-12-02
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04389086 2022-09-06
PelvEx II
Catharina Ziekenhuis Eindhoven
Phase 3 Recruiting
NCT05362617 2022-05-05
mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Unknown
NCT03331640 2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2 Terminated
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04270929 2021-06-01
PANC-001
Roger Williams Medical Center
Phase 1 Withdrawn
NCT02942706 2021-04-30
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT02015923 2021-03-16
CCRe-IV
Hospital Universitari de Bellvitge
Phase 4 Terminated
NCT01298570 2021-01-06
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04003792 2020-10-20
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
Rabin Medical Center
Phase 2 Unknown
NCT02453490 2020-07-14
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
Zhejiang University
Phase 3 Terminated
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02484833 2020-03-31
Erbitux MEtastatic Colorectal Cancer Strategy Study
Catholic University of the Sacred Heart
Phase 3 Completed
NCT01704703 2017-08-01
ULTRA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02978313 2016-11-30
Cetuximab Monotherapy Maintenance Treatment in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT02423226 2015-04-22
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
The First People's Hospital of Changzhou
Phase 2 Completed
NCT01219920 2015-03-11
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT01068132 2014-05-12
Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
Regione Lombardia
Phase 2 Completed
NCT01605344 2014-02-27
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
UNC Lineberger Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01736904 2012-11-29
wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
Fudan University
Phase 2 Unknown
NCT00286130 2012-05-01
Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer
Central European Cooperative Oncology Group
Phase 2 Completed
NCT00313872 2012-01-12
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Samsung Medical Center
Phase 3 Completed
NCT00374036 2011-10-12
Metastatic Gastric Cancer FFCD 03-07
University Hospital, Toulouse
Phase 3 Completed
NCT00839111 2010-09-15
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
Fudan University
Phase 2 Unknown